Company filings, made visual.

Find a company. Follow its revenue through costs and profit.

Market

Find a company or ticker

Coverage includes separate ticker and security records; counts are not unique companies.

Viking Therapeutics, Inc.

TVTX

Filing: SEC 10-Q
Period: Three months ended March 31, 2026
Basis: Editorial filing; Read original SEC 10-Q ↗

Sankey diagram of Viking Therapeutics, Inc.. A complete text table follows the diagram.

Viking Therapeutics Pipeline Revenue Flow

A clinical-stage metabolic-disease pipeline is supported by limited revenue and collaboration activity.

Swipe to explore

Source & review

Read original SEC 10-Q ↗

SEC accession: 0001438533-26-000042
Filed: Date not recorded
Reviewed: Date not recorded
Status: Individual filing review complete

How to read these figures

Labels and displayed flow values are reported filing values or exact disclosed subtotals.

Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.

Viking reports $127.199M of total revenue. The filing discloses $2.707M of license and collaboration revenue; the residual is presented as a development-platform editorial view, not product sales.

View accessible tables

Financial categories · Three months ended March 31, 2026 · Millions of USD
Category	Stage	Value	Notes
Viking Therapeutics revenue	1	$127M	$127.199M reported quarterly revenue
License and collaboration revenue	2	$2.7M	Reported license and collaboration revenue
Therapeutics pipeline	2	$124M	Residual development platform

Financial flows · Millions of USD
From	To	Value
Viking Therapeutics revenue	License and collaboration revenue	$2.7M
Viking Therapeutics revenue	Therapeutics pipeline	$124M